TITAN BIOTECH LTD. Q2 FY27 Results

Titan Biotech's consolidated revenue rose 40.7% YoY to ₹76.46 Cr (₹54.35 Cr a year ago) and 29.2% QoQ (₹59.17 Cr in Q1 FY27), with consolidated PAT up 61.6% YoY to ₹12.55 Cr (₹7.76 Cr) and 15.6% QoQ (₹10.86 Cr). Consolidated PAT runs ₹1.22 Cr ahead of the standalone ₹11.33 Cr print, the gap being the company's share of profit from associates Peptech Biosciences Limited and Titan Media Limited — standalone and consolidated tell broadly the same operating story, with the associate stake adding roughly 11% to the bottom line.

Margins expanded YoY but eased sequentially: OPM (EBITDA/revenue) was 19.63% versus 17.16% a year ago but down from 21.11% in Q1 FY27, while NPM improved to 16.05% from 13.95% YoY but slipped from 17.80% QoQ. Neither period carries exceptional or one-off items (the exceptional-items line is blank throughout), so the YoY margin gain reflects genuine operating leverage on the 40.7% revenue growth rather than a base-effect distortion, while the QoQ give-back points to a cost or mix headwind the filing doesn't break out by segment.

The stock went into the print at ₹331, down 13.6% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

No prior management guidance or concall commentary is on record for this company, and no management press release was available for this result, so neither can be checked against the print. A web search turned up no broker previews or consensus estimates for Titan Biotech's Q2 FY27 — the stock appears to carry no formal analyst coverage — so the vs-street read is unknown rather than a beat or miss. The quarter's other corporate actions sit outside the P&L: the company allotted 1.03 Cr bonus shares in a 1:4 ratio (record date October 23, 2026, after this quarter closed) following a ₹40 Lakh increase in authorized share capital approved at the September 29, 2026 AGM.